- Home
- FFC vs PSNL Comparison
FFC vs PSNL Comparison
Compare FFC & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFC | PSNL |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.7M | 729.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FFC | PSNL |
|---|---|---|
| Price | $15.90 | $10.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 129.0K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 6.79% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.98 | $3.84 |
| 52 Week High | $17.00 | $12.53 |
Technical Indicators
Market Signals| Indicator | FFC | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 63.23 |
| Support Level | $15.68 | $7.26 |
| Resistance Level | $16.10 | $11.28 |
| Average True Range (ATR) | 0.14 | 1.00 |
| MACD | -0.00 | 0.29 |
| Stochastic Oscillator | 49.51 | 68.73 |
Price Performance
Historical ComparisonAbout FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.